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Short-term treatment outcomes 
in human immunodeficiency virus  
type-1 and hepatitis B virus co-infections
Kwamena William Coleman Sagoe1*, Kwabena Obeng Duedu1,2, Francesca Ziga3, Afrakoma Adjoa Agyei4, 
Theophilus Korku Adiku1, Margaret Lartey4, Julius Abraham Addo Mingle1 and Max Arens5
Abstract 
Background: Co-infection of HIV with HBV is common in West Africa but little information is available on the effects 
of HBV on short-term therapy for HIV patients. A 28 day longitudinal study was conducted to examine short-term 
antiretroviral therapy (ART) outcomes in HIV infected individuals with HBV co-infection.
Methods: Plasma from 18 HIV infected individuals co-infected with HBV and matched controls with only HIV infec-
tion were obtained at initiation, and 7 and 28 days after ART. HIV-1 viral load changes were monitored. Clinical and 
demographic data were also obtained from patient folders, and HIV-1 drug resistance mutation and subtype analysis 
performed.
Results: The presence of HBV co-infection did not significantly affect HIV-1 viral load changes within 7 or 28 days. The 
CD4+ counts on the other hand of patients significantly affected the magnitude of HIV-1 viral load decline after 7 days 
(ρ = −0.441, p = 0.040), while the pre-ART HIV-1 VL (ρ = 0.844, p = <0.001) and sex (U = 19.0, p = 0.020) also deter-
mined HIV-1 viral load outcomes after 28 days of ART. Even though the geometric sensitivity score of HIV-1 strains 
were influenced by the HIV-1 subtypes (U = 56.00; p = 0.036), it was not a confounder for ART outcomes.
Conclusions: There may be the need to consider the confounder effects of sex, pre-ART CD4+, and pre-ART HIV-1 
viral load in the discourse on HIV and HBV co-infection.
Keywords: Human immunodeficiency virus, Hepatitis B virus, Co-infection, Antiretroviral therapy, Drug resistance, 
Short-term therapy
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Background
In West Africa, there is a high prevalence of hepatitis 
B virus (HBV) infection [1], and this is also reflected in 
similar high numbers of individuals with HIV also co-
infected with HBV in the sub-region [2–7].
There are conflicting reports on the effects of HBV 
on the response to antiretroviral therapy (ART). Even 
though some studies have shown no significant effects of 
HBV infections on CD4+ recovery and/or suppression of 
HIV-1 plasma viral load (HIV-1 VL) during ART, [8–12] 
others have seen some effects [4, 5, 13–15]. Apart from 
having higher HIV-1 VL, individuals with HIV and HBV 
co-infection in Taiwan on ART were found to have more 
frequent virological failure compared to those with HIV 
alone [13]. In patients co-infected with HIV and HBV 
in Nigeria, the presence of baseline hepatitis B e anti-
gen (HBeAg) was associated with a slower virological 
response (≤400 copies/ml) as compared to those with-
out HBeAg at week 24 [4]. However, this effect of HBeAg 
did not reflect in viral suppression after 48 weeks of ART. 
CD4+ count recovery during ART has been shown to 
be initially blunted in individuals with co-infection as 
compared to those with HIV infection alone [15]. Also, 
large studies done in Africa and Europe have reported 
impaired CD4+ outcomes due to HBV co-infection after 
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varying periods of ART [5, 14]. These seeming discrepan-
cies in outcomes from the various studies may be attrib-
uted to different clinical factors. Since in  vitro studies 
have shown that HBV protein X acts as a trans-activator 
for HIV infections [16, 17], there is the need to under-
stand the effects of the interaction between HIV and 
HBV on short and long term ART outcomes, bearing in 
mind demographical, epidemiological, clinical and viral 
factors.
In the absence of long term HIV-1 VL data and chal-
lenges with adherence after the first few weeks of ART 
in developing countries, changes in HIV-1 VL after 
7  days (HIV-1 VL0–7) and 28  days (HIV-1 VL0–28) of 
ART may be useful in predicting long-term virologi-
cal outcome [18–23]. In a previous study we showed 
that the presence of HBeAg in HIV infected patients 
with HIV and HBV co-infection resulted in more 
severe immune suppression [7]. The objective of this 
study was therefore to use the same study population 
to determine the possible effects of co-infection with 
HBV on short-term ART outcomes in HIV infected 
patients.
Methods
Patients
Briefly, pre-ART plasma samples for a cohort of 138 
patients were screened for HBsAg using a third gen-
eration ELISA, Surase B 96 (TMB), General Biologicals 
Corp, Hsin Chu, Taiwan, and the Core HBsAg rapid test, 
Core Diagnostics, Birmingham, UK. All positive sam-
ples were tested for hepatitis B e antigen and antibody 
(HBeAg and anti-HBe) using the EASE BN-96 (TMB) 
and IgM antibodies to hepatitis B core antigen (anti-
HBc IgM) using the ANTICORASE MB-96 (TMB) kits 
respectively (General Biologicals, Taiwan). Controls for 
all HIV patients with HBV co-infection (n  =  18) were 
chosen based on a baseline CD4+ > or <  100 cells/μl. 
HIV mono-infected patients were matched (1:1) to co-
infected patients on CD4+ cell count. All patients were 
screened with a one-step anti-HIV 1&2 test (SD Bio-
line, Premier Medical Corporation Ltd., India) and were 
shown to be HIV-1 infected. Demographic and clinical 
information was obtained from patient hospital records 
and adherence measured by self-reporting and pill count. 
The various host factors examined as possible confound-
ers in this study included age, sex, pre-ART CD4+, and 
WHO clinical disease staging, while the viral factors were 
HIV-1 subtypes and drug resistance mutations (HIV-1 
DRMs).
Ethics and consent
The study was approved by the University of Ghana Med-
ical School Ethics and Protocol Review Committee and 
written informed consent was obtained from patients 
before enrolment in the study.
HIV‑1 RNA quantitation and determination of early decay
Aliquots of plasma frozen in volumes of 600 μl at −85 °C 
were used in HIV-1 VL determination using the COBAS 
Amplicor Monitor v1.5 tests and the COBAS Amplicor 
analyzer (Roche Diagnostics GmbH, Mannheim, Ger-
many). To ensure that marginal differences did not affect 
viral load analysis, all plasma samples were frozen in ali-
quots to avoid multiple freeze-thaws, and new frozen 
plasma vials at −85 °C were mainly used in determining 
viral loads. HIV-1 VL was determined in duplicates at 
baseline, days 7 and 28 to reduce errors inherent within 
the Amplicor Monitor v1.5 assay. Since the lower limits of 
the standard monitor assay was 400 copies/ml, viral load 
values <400 copies/ml were considered as 400 copies/ml.
All HIV-1 VL analysis were done with the log values 
and plasma viral decay was measured as HIV-1 VL0–7 
and HIV-1 VL0–28. Since HIV-1 VL change within 6 days 
after ART (HIV-1 VL0–6) <0.96 log or ≥1.68 log indicated 
a likelihood for poor and good response good response 
to ART respectively [21], the proportions of patients who 
had <0.96  log and ≥1.68  log were also determined. The 
proportion of patients with HIV-1 VL0–28 of ≥2.58  log 
which may reflect on the possibility of having sustained 
HIV-1 VL suppression was also done for patients with 
day 28 plasma samples [22].
Primary HIV‑1 mutations
Since HIV-1 DRM may be subtype related [24], the 
possible confounder role of primary HIV-1 DRMs and 
subtype on short-term ART was also investigated. The 
High Pure Viral RNA Kit (Roche Diagnostics GmbH, 
Mannheim, Germany) was used for the isolation of 
HIV-1 RNA in plasma. Partial polymerase genes (1065–
1372  bp) were amplified with a nested PCR using six 
primers and a modified version of a protocol published 
previously [25]. Reverse transcription was done using 
the Titan One Tube RT-PCR system (Roche Diagnos-
tics GmbH, Mannheim, Germany). The original pro-
tocol was modified to obtain polymerase (pol) gene 
fragment spanning all the protease (PR) and up to 230 
amino acids in the reverse transcriptase gene (RT). The 
Techne TC-3000 thermocycler (Techne Incorporated, 
Burlington, NJ, USA), was used for all RT-PCR reac-
tions. The RT-PCR products were cleaned with the High 
Pure PCR Product Purification Kit (Roche Diagnostics 
GmbH, Mannheim, Germany). The Big Dye Termina-
tor Cycle sequencing kit v3.1 and the ABI PRISM 3100 
Genetic Analyzer (Applied Biosystems International 
Incorporated, Foster City, USA) were used for forward 
and reverse sequencing. In addition, a third sequencing 
Page 3 of 9Sagoe et al. Ann Clin Microbiol Antimicrob  (2016) 15:38 
primer (RT-sec-1-S: 5′ CAA AAA TTG GGC CTG 
AAA ATC CAT A 3′) was used to ensure that the region 
towards the end of the nucleotides needed for the first 
227 amino acids in the RT region were obtained. The 
ViroSeq HIV-1 Genotyping System v2 (Celera Diag-
nostics, Foster City, Calif, USA) was used as an alterna-
tive method to sequence the pol genes of HIV-1 strains 
which were difficult to amplify with the in-house assay 
[25].
Phylogenetic relationships were determined using a par-
tial pol region containing 867 nucleotides and a RT region 
covering with 691 nucleotides and methods as described 
previously [26]. This was done to ensure that subtyping 
of the RT sequences was truly representative of the pol 
region. Sequences used for phylogeny and in the FASTA 
format were submitted to the Stanford University data-
base (http://www.HIVdb.stanford.edu) for interpretation 
of resistance and assignment of subtype. Mutation scores 
were used to derive genotypic sensitivity scores (GSS) 
based on specific antiretroviral drugs used by patients, 
and this was done using comments from the Stanford 
database. If the mutation site was dimorphic then the 
total score was divided into two and the value used as the 
GSS. The GenBank accession numbers of the sequences 
used in this study are HQ170612–HQ170613, HQ170615, 
HQ170617–HQ170625, HQ529236–HQ529243, HQ529-
245, HQ529247, HQ529249, HQ529251, HQ529253–
HQ529260, HQ529262 and HQ529263.
Analysis of data
The various variables included age, gender, pre-ART 
CD4+, WHO clinical disease staging, HIV-1 subtypes, 
GSS, ARVs, patient’s adherence, pre-ART HIV-1 VL and 
changes within the first 28 days of ART, and co-infection 
status of patients. For analysis involving HIV-1 subtypes, 
the CFR02_AG strains and non-CRF02_AG were consid-
ered as separate groups.
The Mann–Whitney U and Kruskal–Wallis tests were 
used to compare the effects of HBV co-infection on 
HIV-1 VL0–7 and HIV-1 VL0–28. In order to assess the 
possibility of viral and host factors as confounders for 
HIV-1 VL0–7 and HIV-1 VL0–28 outcomes due to HBV 
co-infection, the Mann–Whitney U and Spearman’s 
correlation tests was used to determine the effects of 
the other study variables on HIV-1 VL0–7 and HIV-1 
VL0–28 for all study subjects. Furthermore, since an 
HIV-1 VL decline <0.96 log or ≥1.68 log and ≥2.58 log 
may determine long term outcomes for patients on ART 
by day 7 and 28 respectively [18, 22], a stepwise bivari-
ate logistic regression for HIV-1 VL decline <0.96 log or 
≥1.68 log and ≥2.58 log was also done with all variables 
significantly affecting ART outcomes (pre-ART HIV-1 
VL, pre-ART CD4+, and sex). All statistical analysis 
were done with SPSS Version 17 software (SPSS Inc., 
Chicago, Illinois) and the two-tailed p-values of <0.05 
considered as significant.
Results
A description of the demographic and clinical charac-
teristics of HIV infected patients with HBV co-infection, 
and those with HIV infection alone is shown in Table 1. 
Generally, patients had low CD4+ counts with majority 
having WHO clinical stage 3.
Polymerase gene polymorphisms
A total of 34 samples were amplified successfully using 
the two PCR methods and 30 were subtyped using phylo-
genetic analysis (Fig. 1). The relatively shorter sequences 
(KAF23, KAF56, KAF104 and KAF109) were subtyped 
solely using the Stanford database drug resistance pro-
gram (http://www.HIVdb.stanford.edu). Majority of the 
subtypes were CRF02_AG, with 5 subtype G, 1 CRF06_
cpx, 1 subtype A, and 1 CRF01_AE (Fig. 1), but the Stan-
ford database drug resistance program failed to correctly 
infer subtypes A3 and CRF06_cpx (Table 2). The topolo-
gies of the 867 pol and 691 RT phylogenetic trees were 
similar thus confirming subtypes assigned to the RT 
region. There were no major drug resistance mutations 
but seven HIV-1 stains had some level of drug resistance 
(Table  2). The V108I mutation seen in KAF41, KAF71 
Table 1 Description of study population
a For variable with n number of patients indicated, the percentages were 
calculated based on those values
Variablesa Co‑infected
(n = 18)
HIV infections 
alone
(n = 18)
Demographic data
 Sex, female (%, CI) 11 (61.1) 11 (61.1)
 Age (median, IQR) 36.5 (33.8–41.5) 35.5 (30.8–45.2)
Clinical parameters
 CD4+ (median/IQR) 137 (35–197) 125 (50–182)
 WHO disease stage
  2 (n = 3) 2 (11.1 %) 1 (5.6 %)
  3 (n = 38) 15 (83.3 %) 13 (72.2 %)
  4 (n = 5) 1 (5.6 %) 4 (22.2 %)
 ARV combination
 d4T + 3TC + NVP (n = 8) 4 (22.2 %) 4 (22.2 %)
 d4T + 3TC + EFV (n = 11) 4 (22.2 %) 3 (16.7 %)
  CBV + NVP (n = 15) 5 (27.8 %) 6 (33.3 %)
  CBV + EFV (n = 12) 5 (27.8 %) 5 (27.8 %)
 Hepatitis virus markers
  HBeAg 10 (55.6 %) –
  Anti-HBe 8 (44.4 %) –
  Anti-HBc IgM 0 (0.0 %) –
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and KAF104 reduces NVP and EFV susceptibilities by 
about twofold. The V118I mutation which is a polymor-
phic accessory NRTI-resistance mutation that occurs in 
combination with multiple TAMs, was seen in the only 
subtype A3 identified in the study (KAF33). Finally, the 
V179E mutation which causes low level resistance in 
NVP and EFV was seen in KAF69 and KAF71, but as a 
polymorphic site in KAF41 (V179EV) (Table  2). The 
GSS were influenced by the HIV-1 subtypes (U = 56.00; 
p = 0.036).
Outcomes after short‑term HAART
A total of 35, 22 and 20 HIV-1 VL quantitation results 
were available for pre-ART, day 7 and day 28 plasma sam-
ples respectively. The presence of HBV co-infection or 
any HBV marker did not significantly affect HIV-1 VL0–7 
and HIV-1 VL0–28 (Table  3). Apart from sex, pre-ART 
CD4+, and pre-ART HIV-1 VL, all the other variables did 
not influence HIV-1 VL0–7 and HIV-1 VL0–28 (Table  4). 
The CD4+ of patients significantly affected the magnitude 
of HIV-1 VL0–7 (ρ = −0.441, p = 0.040), while the pre-
ART HIV-1 VL also determined HIV-1 VL0–28 outcomes 
(ρ = 0.844, p = <0.001). HIV-1 VL decline <0.96  log or 
≥1.68  log and ≥2.58  log was generally not affected by 
majority of the variables. Patients who had ≥1.68  log 
decline in HIV-1 VL were marginally likely to have higher 
CD4+ counts than those who did not achieve a 1.68  log 
decline (p = 0.065). The pre-ART HIV-1 VL was signif-
icantly higher in those who had achieved an HIV-1 VL 
decline of ≥2.58 log after 28 days of ART (p = 0.006). 
A bivariate logistic regression using an HIV-1 VL 
decline <0.96 log revealed that CD4+ was marginally sig-
nificant (p = 0.067). Also, pre-ART HIV-1 VL was mar-
ginally significant after a decline of ≥2.58 after 28 days of 
ART (p = 0.051).
Discussion
Relatively few studies have evaluated the usefulness 
of early HIV-1 plasma viral decay, HIV-1 VL0–7 or 
HIV-1 VL0–28, in determining long term outcomes after 
initiation of ART or in determining the efficacy of ART 
regimens [18–22, 27–30]. One of such studies showed 
that HIV-1 VL0–6 was as good as using the decay constant 
in determining the likelihood for poor and good response 
to ART [21]. Furthermore, in a fairly large population of 
ART naïve adults, HIV-1 VL0–7 was significantly asso-
ciated with HIV-1 VL after 48  weeks of ART but not 
after 24 weeks [18]. These studies therefore help to pro-
vide early warning indicators for long term outcomes of 
patients on ART. Even though a few patients in this study 
were estimated to have a reduced adherence this did 
not affect the short term outcomes of this study as has 
been seen elsewhere [22]. Thus with the relatively small 
population of individuals co-infected with HIV and HBV, 
adherence was not an issue in the analysis of the data. 
Admittedly, the lack of continuous HIV-1 VL data for all 
36 patients may have created gaps in the analysis of data. 
In spite of this limitation, it is necessary to mention that 
the whole study population was considered in determin-
ing the effects of the different study variables on short-
term ART outcomes.
In sub-Saharan Africa, individuals with HIV infec-
tions may report to ART clinics late and therefore not 
start ART when they are due [31]. This may reflect in low 
CD4+ counts which are indicators for treatment failure 
[32]. This is consistent with the parameters of the study 
population in which majority of the patients were classi-
fied as being in WHO clinical stage 3, and CD4+ affected 
outcomes after 7  days of ART. The HIV-1 VL0–7 has 
been shown to have a strong correlation with the phase 
1 constant of HIV-1 decay [21, 23], and this correlation 
was weaker when calculated 3, 4 or 10  days after onset 
of ART but may be similar when done at day 6 [21]. The 
choice of day 7 HIV-1 VL as an indicator and the fact that 
CD4+ does affect its outcome, therefore suggests that 
those who are severely immunocompromised are more 
likely to have poorer outcomes during ART. The blunt-
ing of CD4+ in individuals with HIV and co-infected with 
HBV at different periods of ART [5, 33], may therefore 
affect HIV-1 VL outcomes at a point in time as shown 
(See figure on next page) 
Fig. 1 Phylogenetic trees using partial pol genes of HIV-1; a CRF02_AG, CRF06_cpx, and Subtype G clusters, and b Subtype A cluster. The reference 
subtype [accession number] include: A1 (PS1044 [DQ676872]; Q23 [AF004885]; RW008 [AB253421]; UG037 [AB253429]), A2 (KTB48 [AF286238]; 
CY017 [AF286237]), B (HXB2 [K03455]; 00T36 [AY423387]; BK132 [AY173951]; 1058 [AY331295]), C (BR025 [U52953]; ETH2220 [U46016]; IN21068 
[AF067155]; SK164B1 [AY772699]), D (ELI [K03454]; 4412HAL [AY371157]; A280 [AY253311]; UG114 [U88824]), F1 (VI850 [AF077336]; BR020 
[AF005494]; FIN9363 [AF075703]; MP411 [AJ249238]), F2 (0016BBY [AY371158]; MP255 [AJ249236]; MP257 [AJ249237]; 53657 [AF377956]), G 
(DRCBL [AF084936]; HH8793 [AF061641]; NG083 [U88826]; PT2695 [AY612637]), H (VI991 [AF190127]; VI997 [AF190128]; 056 [AF005496]), J (KTB147 
[EF614151]; 7887 [AF082394]; 7022 [AF082395]), K (EQTB11C [AJ249235]; MP535 [AJ249239]), 01_AE (CM240. [U54771]; TH051. [AB220944]), 02_AG 
(pBD6 [AY271690]; IBNG. [L39106]), 06_cpx (90 [AF064699]; 0359 [AY535659]; G173 [AB286851]), 09_cpx (00IC [AJ866553]; 2911 [AY093605]), 
22_01A1 (BBY [AY371159]), 28_BF 12313 [DQ085872]; 12609 [DQ085873]; 12817 [DQ085874]), 29_BF (16704 [DQ085876]; 11948 [DQ085871]), 
32_06A1 (03+ [AY535660]), 33_01B (007 [DQ366659]; 045 [DQ366662]), 34_01B (2478 [EF165541]), 43_02G (J+ [EU697904]; J++ [EU697907]; 
J+++ [EU697909]), O (ANT70 [L20587])
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by others [4]. This may partly have accounted for the 
observation that HBV co-infection may be associated 
with more frequent virological failure [13]. Pre-ART 
HIV-1 VL has been observed as one of the factors affect-
ing long term outcomes in patients on ART [22]. Since 
this was also observed after 28 days on ART in this study, 
the use of outcomes after 7 and 28 days as representing 
long term outcomes to some extent is justified. Thus, in 
spite of the relatively small study population in this pre-
liminary study, the results to a large extent are consist-
ent with that which is observed in long term studies with 
specific respect to the effects of CD4+.
The studies cited earlier showing somewhat differ-
ences in ART outcomes were conducted in patients 
from different geographical regions. We postulated 
that since there is emerging data suggesting that HIV-1 
subtype may influence the choice of antiretroviral 
drugs (ARVs) [24] then there is a possibility that the 
co-circulation of different subtypes may occur within 
different geographical areas. The presence of primary 
HIV-1 resistance which may be different in different 
subtypes may therefore serve as a confounder in look-
ing at long term outcomes. Even though the GSS did 
not influence HIV-1 VL0–7 and HIV-1 VL0–28 signifi-
cantly, the fact that those with HIV-1 subtype which 
were non CRF 02_AG strains had significantly higher 
GSS brings to the fore the hypothesis that regional 
Table 2 HIV-1 subtype and drug resistance mutations in patients
KAF, patients ID; Cases, individuals infected with HIV and HBV; Controls, those infected with only HIV; Mutationsa/GSSa, HIV-1 drug resistance mutations/genotypic 
sensitivity scores (GSS) based on specific ARVs used by patients as determined by the Stanford database (analyzed on July 8, 2014); HIV-1 VL, pre-HAART HIV-1 plasma 
viral load. Subtypes were determined by the Stanford database
na not available
Cases Controls
KAF Subtype Mutationsa GSSa HIV‑1 VL KAF Subtype Mutationsa GSSa HIV‑1 VL
151 CRF02_AG – 0 5.38 075 CRF02_AG – 0 5.08
083 CRF02_AG – 0 5.74 124 CRF02_AG – 0 5.46
092 CRF02_AG – 0 5.87 023 CRF01_AE na na 5.49
028 CRF02_AG – 0 5.26 130 CRF02_AG/G – 0 5.73
090 G – 0 4.76 033 A/CRF01_AE V118I 0 6.02
056 G na na 5.33 081 CRF02_AG – 0 5.39
071 CRF02_AG V108I, V179E 25 5.16 078 CRF02_AG E138A 0 3.52
120 CRF02_AG – 0 5.65 104 G V108I 15 5.18
026 CRF02_AG – 0 5.76 149 CRF02_AG – 0 4.65
115 CRF02_AG – 0 5.09 074 CRF02_AG – 0 5.73
031 CRF02_AG V90I 0 4.87 137 A/CRF02_AG – 0 5.28
061 CRF02_AG – 0 5.86 010 CRF02_AG – 0 6.33
077 CRF02_AG – 0 5.52 064 na na na 6.45
041 G V108IV, E138A, V179EV 10 4.20 121 CRF02_AG – 0 6.27
156 CRF02_AG – 0 5.54 037 CRF02_AG – 0 5.49
011 CRF02_AG V90I 0 5.31 095 CRF02_AG – 0 6.15
109 CRF02_AG – 0 6.08 019 G – 0 6.16
200 na na na na 024 CRF02_AG – 0 4.46
Table 3 HIV-1 plasma viral loads in  HIV infected patients 
with HBV infection
Groups Mean rank Mann–Whitney U p value
Baseline
 HIV only (n = 18) 19.56 125.00 0.355
 Co-infected (n = 17) 16.37
Day 7
 HIV only (n = 11) 12.14 53.50 0.646
 Co-infected (n = 11) 10.86
Day 28
 HIV only (n = 10) 11.70 38.00 0.287
 Co-infected (n = 10) 9.30
VL0–7
 HIV only (n = 11) 10.00 44.00 0.287
 Co-infected (n = 11) 13.00
VL0–28
 HIV only (n = 10) 12.20 33.00 0.199
 Co-infected (n = 10) 8.80
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subtype differences needs to be factored into the dis-
cussion of the effects of HBV on outcomes of ART. The 
possibility of primary HIV-1 DRMs influencing some 
virological outcomes in HBV co-infection in different 
geographical areas cannot be ruled out. This assertion 
is buttressed by the fact that primary HIV-1 DRMs are 
likely to result in treatment failure after 12 months of 
ART [34].
The hypothesis that HBV protein X may cause differ-
ent outcomes in ART in those with and without HBV 
co-infection is not suggested in this study. However, 
CD4+, pre-ART HIV-1 VL and sex need to be considered 
as possible confounders. It is unclear how the latter will 
affect virological outcome.
As compared to other studies in Ghana, the muta-
tions seen confirm the absence of major HIV-1 DRM 
in treatment naïve patients [35, 36]. Since no trans-
mitted HIV-1 drug resistance mutations were seen, 
most of the mutations were more likely to be subtype 
or strain related. In spite of the small study popula-
tion as compared to others [35, 37, 38], it seems that 
the V108I mutation may be fairly common in naïve 
patients.
Conclusion
Pre-ART CD4+, pre-ART HIV-1 pVL, and sex may be 
important in determining ART outcomes in individuals 
on ART with HIV and HBV co-infections.
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Table 4 Effect of host and HIV-1 viral factors on day 7 and 28 changes in HIV-1 plasma viral load
Significant p values are in italics
U, Mann–Whitney U test; χ2 (df ), Kruskal–Wallis H test; Co-infection, HIV and HBV co-infection; VL0–7 HIV-1 plasma viral load changes after 7 days of therapy; VL0–28 
HIV-1 plasma viral load changes after 28 days of therapy
Variables Categories HIV‑1 VL0–7 (N = 30) HIV‑1 VL0–28 (N = 22)
Mean rank U/χ2 (df) p value Mean rank U/χ2 (df) p value
HBV status HIV alone 10.00 (n = 11) 44.0 0.300 12.20 (n = 10) 33.0 0.218
Co-infection 13.00 (n = 11) 8.80 (n = 10)
Sex Male 12.86 (n = 7) 43.0 0.503 15.35 (n = 9) 19.0 0.020
Female 10.87 (n = 15) 8.29 (n = 11)
WHO clinical stage Stage 1 4.25 (n = 2) 2.794 (2) 0.247 9.00 (n = 1) 0.068 (2) 0.966
Stage 2 12.09 (n = 17) 10.56 (n = 16)
Stage 3 13.00 (n = 3) 10.67 (n = 3)
Antiretroviral drugs d4T + 3TC + EFV 11.00 (n = 2) 0.737 (3) 0.864 10.50 (n = 2) 3.182 (3) 0.364
d4T + 3TC + NVP 12.83 (n = 6) 9.75 (n = 4)
CBV + EFV 12.25 (n = 8) 13.13 (n = 8)
CBV + NVP 10.06 (n = 8) 7.50 (n = 6)
Mutations Present 5.75 (n = 2) 8.5 0.292 9.5 (n = 4) 26.0 0.878
Absent 10.75 (n = 17) 10.75 (n = 16)
HIV-1 subtype 02AG 10.41 (n = 17) 24 0.410 9.5 (n = 4) 37 0.898
Non 02AG 13.50 (n = 4) 10.75 (n = 16)
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